Bassetty Karthik C, Thomas Anitha, Chandy Rachel G, Thomas Dhanya S, Thomas Vinotha, Peedicayil Abraham, Sebastian Ajit
Department of Gynaecologic Oncology, Christian Medical College, Vellore, 632004 India.
J Obstet Gynaecol India. 2022 Aug;72(Suppl 1):334-339. doi: 10.1007/s13224-022-01659-2. Epub 2022 Apr 6.
Vulval Intraepithelial Neoplasia 3 (VIN) is a chronic, premalignant condition affecting the vulval skin. The age standardised incidence is approximately one per 100,000 women, with a peak at 30-49 years of age, and has risen over recent decades. This study would analyse the pattern of presentation, diagnosis, treatment and follow up of patients diagnosed with VIN 3 over a period of ten years at a tertiary care centre in India.
This was a retrospective study conducted on all patients diagnosed to have VIN 3 between 1 January 2010 to 30 November 2019 in the Department of Gynaecologic Oncology, Christian Medical College, Vellore were included in this study. The outpatient records of the patients were obtained from an electronic registry.
A total of 18 patients were diagnosed of VIN 3 during this time period. Sixteen patients were older than 50 years. Abnormal PAP was noted in 10 patients (HSIL-7, LSIL-2, ASC-H-1). Four patients had coexisting VAIN 3. About 16 patients underwent primary simple vulvectomy or wide local excision. Two patients were managed conservatively. Nine patients had recurrence with mean disease free interval of 12.5 months (4-36 months). Cryotherapy was used in 2 patients. Imiquimod was used in 3 patients. Surgical margins was achieved in 7 patients out of which 5 patients had recurrence. About 50% of patients with involved margins on biopsy had recurrence. Mean duration of follow up was 17 months (4-105 months). About 8 patients developed squamous cell carcinoma of genital tract on follow up.
VIN 3 has a high rate of progression to invasive SCC. Regression of VIN is rare. Proper follow up and treatment of VIN 3 goes a long way in preventing the morbidity associated with vulval cancer.
外阴上皮内瘤变3级(VIN)是一种影响外阴皮肤的慢性癌前病变。年龄标准化发病率约为每10万名女性中有1例,发病高峰在30 - 49岁,且近几十年来呈上升趋势。本研究将分析在印度一家三级护理中心确诊为VIN 3的患者在十年期间的临床表现、诊断、治疗及随访模式。
这是一项回顾性研究,纳入了2010年1月1日至2019年11月30日期间在韦洛尔基督教医学院妇科肿瘤学系确诊为VIN 3的所有患者。患者的门诊记录从电子登记处获取。
在此期间共诊断出18例VIN 3患者。16例患者年龄超过50岁。10例患者出现异常巴氏涂片结果(高级别鳞状上皮内病变 - 7例,低级别鳞状上皮内病变 - 2例,非典型鳞状细胞不排除高度病变 - 1例)。4例患者同时存在阴道上皮内瘤变3级。约16例患者接受了原发性单纯外阴切除术或广泛局部切除术。2例患者采用保守治疗。9例患者复发,平均无病间期为12.5个月(4 - 36个月)。2例患者使用了冷冻疗法。3例患者使用了咪喹莫特。7例患者实现了手术切缘阴性,其中5例复发。活检切缘阳性的患者中约50%复发。平均随访时间为17个月(4 - 105个月)。随访期间约8例患者发生了生殖道鳞状细胞癌。
VIN 3进展为浸润性鳞状细胞癌的发生率很高。VIN消退罕见。对VIN 3进行适当的随访和治疗对于预防外阴癌相关的发病率大有帮助。